Sunday, June 29, 2014
Australia - Test For Prostate Cancer Using Semen
A microRNA-based test for prostate cancer could help distinguish aggressive tumors from slow growing ones and prevent unnecessary biopsies.
AsianScientist (Jun 11, 2014) – The discovery that seminal fluid (semen) contains biomarkers for prostate cancer could lead to improved diagnosis and management of the disease. A study published in the journal Endocrine-Related Cancer has shown that the presence of certain microRNAs in seminal fluid indicates not only whether a man has prostate cancer, but also the severity of the cancer.
University of Adelaide research fellow and lead author Dr. Luke Selth says that the commonly used prostate-specific antigen (PSA) test is by itself not ideal to test for the cancer.
“While the PSA test is very sensitive, it is not highly specific for prostate cancer,” Dr. Selth says. “This results in many unnecessary biopsies of non-malignant disease. More problematically, PSA testing has resulted in substantial over-diagnosis and over-treatment of slow growing, non-lethal prostate cancers that could have been safely left alone.
“Biomarkers that can accurately detect prostate cancer at an early stage and identify aggressive tumours are urgently needed to improve patient care. Identification of such biomarkers is a major focus of our research,” he says.
Using samples from 60 men, Dr. Selth and colleagues discovered a number of small ribonucleic acid (RNA) molecules called microRNAs in seminal fluid that are known to be increased in prostate tumours. The study showed that some of these microRNAs were surprisingly accurate in detecting cancer.
“The presence of these microRNAs enabled us to more accurately discriminate between patients who had cancer and those who didn’t, compared with a standard PSA test,” Dr. Selth says.
“We also found that the one specific microRNA, miR-200b, could distinguish between men with low grade and higher grade tumours. This is important because, as a potential prognostic tool, it will help to indicate the urgency and type of treatment required.”
This research builds on previous work by Dr. Selth’s team, published in the British Journal of Cancer, which demonstrated that microRNAs in the blood can predict men who are likely to relapse after surgical removal of their prostate cancer.
The research team is now expanding on these studies using larger patient groups to validate their findings.
The article can be found at: Selth et al. (2014) Human Seminal Fluid as a Source of Prostate Cancer Specific microRNA Biomarkers.